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Molecular switches are the fundamental building blocks in the ﬁeld of synthetic biology. The major-
ity of these switches is based on protein–protein, protein–DNA or protein–RNA interactions that are
responsive towards endogenous metabolites or external stimuli like small molecules or light. By the
rational and predictive reassembling of multiple compatible molecular switches, complex synthetic
signaling networks can be engineered. Here we review how these switches were used for the regu-
lation of important cellular processes at every level of the signaling cascade. In the second part we
review how these switches can be assembled to open- and closed-loop control signaling networks
and how these networks can be applied to facilitate cattle reproduction, to treat diabetes or to
autonomously detect and cure disease states like gouty arthritis or cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Synthetic biology is a relatively new discipline which aims to
engineer novel biological systems with useful and predictable
functions by combining modular, well-characterized genetic parts
in a rational and systematic manner [1–8]. The key elements of
these modular parts are molecular switches that are based on pro-
tein–protein, protein–DNA or protein–RNA interactions [9]. These
interactions can be triggered by endogenous metabolites or by
the external application of small molecules, metabolites or physi-
cal cues such as light of a speciﬁc wavelength. Moreover, naturally
occurring or engineered switchable signaling proteins like ion
channels or enzymes can directly change their conformation or
activity towards an external stimulus. During the past years, many
molecular switches have been identiﬁed and characterized that are
now available for the construction of complex synthetic signaling
networks. In this article we ﬁrst describe recently developed
molecular switches that were used to control cellular processes
at every level of the signaling cascade and we exemplarily show
how these switches can be combined to complex therapeutic
signaling networks.cal Societies. Published by Elsevier
iversity of Freiburg, Schänz-
03 97660.
rg.de (W. Weber).2. Molecular switches
In this chapter we review how molecular switches were used as
molecular building blocks to obtain control of biological processes
at different cellular levels – starting at the outside of the cell at the
receptor level, continuing to signaling pathway and gene expres-
sion control and ﬁnally to the regulation of protein degradation.
2.1. Control at the receptor level
In the past, several studies described membrane receptor acti-
vation based on chemically induced protein dimerization [10,11].
However, these systems allowed only limited temporal and no
spatial control. Therefore, novel optogenetic approaches were
developed for the activation of membrane channels and receptors
by the transgenic expression of microbial or animal opsins
(Table 1). After binding of the organic cofactor retinal, which seems
to be present in the central nervous system of all vertebrates, the
opsins are functional and called rhodopsins [12]. So far, channel-
rhodopsins, halorhodopsins, rhodopsin-GPCR (G protein-coupled
receptor) chimeras and melanopsin have been used as opsin-based,
single-component optogenetic tools in mammalian cells.
Channelrhodopsin-2 (ChR2) [13] from Chlamydomonas reinhardtii
is a blue (460 nm) light-activated cation-speciﬁc ion channel that
allows reliable control of neuronal spiking in a millisecond-time-
scale and of inhibitory and excitatory synaptic transmission in
mammalian neurons [14]. In several studies it was shown thatB.V. Open access under CC BY-NC-ND license.
Table 1
Overview of the switchable signaling proteins described in this review. The proteins are either activated by light of a speciﬁc wavelength or by a small molecule.
Protein Stimulus Description References
ChR2 Blue (460 nm) light Blue light induces cation permeability of the ion channel channelrhodopsin-2 (ChR2) [13,14]
FAK-iFKBP Rapamycin A truncated version of FK506- and rapamycin-binding protein FKBP12 (iFKBP) is introduced into the
catalytic domain of the focal adhesion kinase (FAK) thus inactivating its enzymatic activity. Addition of
rapamycin restores catalytic activity
[27]
Melanopsin Blue (470 nm) light Constitutive expression of melanopsin in mammalian cells allows blue-light triggered transcription
control of a PNFAT-driven reporter
[51]
NpHR Yellow (580 nm) light Yellow light illumination activates the halorhodopsin chloride pump NpHR [19]
OptoXRs,
e.g. opto-b2AR
Green (500 nm) light In OptoXRs, the intracellular loops of rhodopsin are replaced with those of GPCRs. Green light triggers
activation of the GPCR-respective signaling pathway
[21]
PAC Blue (380–480 nm) light Activity of photoactivated adenylyl cyclase (PAC) is increased upon blue light illumination [28]
VChR1 Yellow (589 nm) light Illumination of the Volvox ion channel channelrhodopsin-1 (ChR1) with yellow light triggers
permeability for cations
[18]
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was used to restore visual function in mouse models of blindness
[15], to stimulate heart muscle [16] or to study amygdala circuits
involved in anxiety and fear in mice [17]. Similar to ChR2, Volvox
carteri Channelrhodopsin-1 (VChR1) is a yellow (589 nm) light-
induced non-speciﬁc cation channel which allows precisely timed
light-triggered depolarization of neurons [18]. In contrast to the
excitatory channelrhodopsins, halorhodopsins are yellow
(580 nm) light-inducible chloride ion pumps that can be used
as optogenetic tools for neuronal inhibition [19]. Zhang et al.
showed that the archaeal halorhodopsin NpHR from Natronomon-
as pharaonis can be used for temporally precise optical inhibition
of neural activity and that due to the red-shifted excitation
maximum in comparison to ChR2, both ion channels can be used
simultaneously in mammals [19]. Moreover, simultaneous expres-
sion of ChR2 and NpHR was used to engineer an optically con-
trolled cardiac pacemaker in zebraﬁsh cardiomyocytes [20].
Besides using microbial opsins as ion channels or pumps, rhodop-
sin-GPCR chimeras (termed OptoXRs) have been engineered to
control receptor-initiated biochemical signaling pathways in a
temporally precise manner by light [21]. For the construction of
OptoXRs, the intracellular loops of the bovine GPCR rhodopsin
were replaced with those of Gq-coupled human a1a- or Gs-coupled
hamster b2-adrenergic receptors thus rewiring rhodopsin from the
Gt to the Gq or Gs signaling pathway, respectively. By illumination
with 500 nm green light, the OptoXRs and thereby the correspond-
ing signaling pathways were able to be activated in vitro and in
mice [21]. In another study, the Gi/o-coupled 5-HT1A receptor was
linked to rhodopsin by the same approach [22].
These studies on opsin-derived molecular switches impres-
sively demonstrated how cell fate and function can precisely be
controlled by externally inducing receptor activity. This concept
might be extended to other naturally occurring receptors respon-
sive for example to metabolites [23], cytokines [24], olfactory
chemicals [25] or pathogen-associated stimuli [26].
2.2. Regulation of signaling pathways
Besides engineering the upstream receptor level, signaling
pathways in mammalian cells can be controlled by rendering pro-
teins responsive to an exogenous stimulus. In a recent study, Kar-
ginov et al. engineered rapamycin-dependent kinases using an
allosteric regulation strategy [27]. For this purpose a truncated ver-
sion of the FK506- and rapamycin-binding protein FKBP12 (iFKBP)
was introduced into the highly conserved catalytic domain of the
focal adhesion kinase (FAK) thus inactivating its catalytic activity.
Addition of rapamycin restored enzymatic activity probably by
reducing the iFKBP-induced ﬂexibility of the catalytic domain. By
this approach, FAK activity was controlled within minutes in livingcells. Since the tyrosine kinase Src and the serine/threonine kinase
p38were able tobe similarly regulated by insertion of iFKBP at
analogous sites, it is likely that this approach is applicable to fur-
ther kinases [27].
Small molecules like rapamycin are commonly used to control
protein activity and interaction in a temporal manner but they only
allow limited spatial control and reversibility. To address this chal-
lenge novel light-dependent protein switches were developed that
allow ﬁne spatiotemporal control of signaling pathways. In 2006,
Schröder-Lang et al. published a method for the fast light-depen-
dent control of the cellular cyclic adenosine monophosphate
(cAMP) level by expressing the photoactivated adenylyl cyclase
(PAC) from Euglena gracilis in Xenopuslaevis, human embryonic kid-
ney (HEK-293) cells and Drosophila melanogaster [28]. This aden-
ylyl cyclase contained two subunits that harbored each two FAD-
binding (ﬂavin adenine dinucleotide) BLUF-type receptor domains
and showed increased catalytic activity upon 380–480 nm blue
light illumination. They showed that the blue light-triggered in-
creased cAMP level was sufﬁcient to activate cAMP-dependent
protein kinase (PKA) and cyclic nucleotide-gated (CNG) channels.
This ﬁne spatiotemporal control of the ubiquitous second messen-
ger cAMP could be a useful tool in future signaling pathway studies
[28]. However, this approach is based on a naturally light-sensitive
enzyme and can therefore not easily be transferred to other
proteins. In the following, three more general strategies for the reg-
ulation of protein activity by light are described.
Wu et al. engineered a photoactivatable version of the actin
cytoskeletal-regulating GTPase Rac1 using the protein light switch
phototropin 1 of Avena sativa [29]. In phototropin 1 a LOV2 (light,
oxygen or voltage) domain is interacting with its carboxy-terminal
helical extension Ja in the dark while illumination with 458 or
473 nm leads to the formation of a covalent bond between ﬂavin
and Cys450 of LOV2 resulting in dissociation and unwinding of
the Ja helix. To control the motility of living cells, the LOV2-Ja do-
main was fused amino-terminally to a constitutively active variant
of Rac1. In the dark, the closed conformation of the Ja helix steri-
cally blocked binding of effector proteins to Rac1 while 458 nm
illumination induced LOV2-Ja unwinding followed by 10-fold
derepression of Rac1 activity. Transfection of the photoactivatable
Rac1 into mouse embryonic ﬁbroblasts allowed precise spatial and
temporal control of Rac1 activity and subsequent lamellipodial cell
protrusions. Structural studies indicated that the engineered sys-
tem could be used as blueprint for the construction of other caged
GTPases [29].
Since many cellular processes and signal transduction cascades
are based on protein–protein interactions (Table 2), their control
exhibits a universal and useful tool for the investigation of
signaling pathways. In the following, two approaches allowing
ﬁne spatiotemporal control of protein–protein interactions in
Table 2
Overview of switchable protein–protein interactions. Hetero- or homodimerization of proteins can either be induced by light of a speciﬁc wavelength (top) or by application of a
ligand (bottom).
Protein 1 Protein 2 Stimulus Description References
Light-induced protein interactions
CRY2 CIB1 Blue (461 nm or 488 nm) light Cryptochrome 2 (CRY2) rapidly interacts with CIB1 upon blue light
illumination and dissociates thereof in the dark within 12 min
[38]
FKF1 GI Blue (450 nm) light Heterodimerization of FKF1 and GIGANTEA (GI) is induced by blue light
within tens of minutes and dissociation occurs in the dark after several hours
[31]
LOV2 Ja Blue (458 nm or 473 nm) light LOV2 interacts with its C-terminal helical extension Ja in the dark while blue
light illumination results in dissociation and unwinding of the Ja helix
[29]
PhyB PIF6 Red (650 nm)/far-red (750 nm) light The interaction between phytochrome B and its phytochrome interacting
factor PIF6 is induced by red and reversed by far-red light both at a
subsecond timescale
[30]
Ligand-induced protein interactions
FKBP12 Calcineurin A FK506/rapamycin FK506 induces interaction between FKBP and calcineurin A that can be
blocked by rapamycin
[61]
FKBP12 FKBP12 FK1012 FK1012 (semisynthetic dimer of FK506) promotes homodimerization of
FKBP12
[62–64]
FKBP12 FRB Rapamycin FKBP12 is interacting with the FRB domain of FRAP in presence of rapamycin [65,66]
FM FM FK506
Rapamycin
The FM protein forms homodimers that can be completely dissociated within
minutes by monomeric ligands
[67]
GyrB GyrB Coumermycin/novobiocin Coumermycin induces interaction of two Gyrase B subunits. GyrB
homodimers are dissociated by novobiocin
[68–70]
SBD HSP90 Natural steroid hormones (e.g.
ecdysone) or synthetic ligands (e.g.
tamoxifen, RU486)
Interaction of steroid-binding domains (SBD) with the inhibitory HSP90
complex can be disrupted by natural or synthetic steroid hormones
[71–73]
Streptavidin Protein of
interest with
AVITAG
Biotin E. coli BirA biotin ligase irreversibly ligates biotin to the AVITAG peptide (15
amino acids) thereby inducing strong interaction between streptavidin and
the protein of interest
[74,75]
Fig. 1. Light-induced spatiotemporal control of cell signaling. The system is based
on the red/far-red light-dependent interaction between phytochrome B (PhyB) and
its phytochrome interacting factor PIF6. Phytochrome B was targeted via an
mCherry linker and a CAAX prenylation signal to the plasma membrane while PIF6
was linked via YFP to the isolated catalytic module of the guanine nucleotide
exchange factor RacGEF Tiam (Tiam-DH-PH). Focal 650 nm red light illumination
triggered the interaction of PIF6 and PhyB, thereby recruiting Tiam-DH-PH to the
illuminated spot at the plasma membrane and resulting in the activation of the
respective Rho-family GTPase Rac1 and the formation of lamellipodia.
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oped a system to control cellular signaling using the light-depen-
dent interaction between Arabidopsis thaliana holophytochrome B
(apoPhyB bound to the chromophore phycocyanobilin) and its
phytochrome interacting factor PIF6 [30]. A screen with truncated
versions in mammalian cells revealed that amino acids 1–908 of
PhyB and 1–100 of PIF6 showed dimerization at 650 nm and dis-
sociation at 750 nm light in a fully reversible manner at a time
scale of seconds. This system was used to achieve spatiotemporal
control of cell shape in NIH/3T3 mouse ﬁbroblasts by fusing PIF6
via a YFP linker to the isolated catalytic modules (DH-PH do-
mains) of the guanine nucleotide exchange factors RacGEF Tiam
(Tiam-DH-PH) or Cdc42GEF intersectin (ITSN-DH-PH) and target-
ing PhyB via an mCherry or CFP linker and a CAAX prenylation
signal to the plasma membrane (Fig. 1). Focal 650 nm red light
illumination induced recruitment of the PIF6 fusion proteins to
the illuminated spot at the plasma membrane and subsequently
triggered the activation of the respective Rho-family GTPases
Rac1 or Cdc42 resulting in the formation of lamellipodia or ﬁlopo-
dia, respectively [30].
A similar approach to control lamellipodia formation using the
proteins FKF1 and GIGANTEA (GI) from the ﬂowering control net-
work of Arabidopsis thaliana was published by Yazawa et al. in
2009 [31]. FKF1 contains a light-sensitive LOV domain that is form-
ing a covalent bond with the abundant ﬂavin mononucleotide
(FMN) upon 450 nm illumination thus enabling binding of GI to
FKF1. By targeting GI to the plasma membrane via an mCherry lin-
ker and a CAAX prenylation signal and expressing a constitutively
GTP-bound but CAAX-devoid Rac1 mutant fused to FKF1 via YFP,
lamellipodia formation was triggered by 450 nm illumination and
subsequent Rac1 relocalization to the plasma membrane. In con-
trast to the PhyB-PIF6 system, formation of the FKF1-GI heterodi-
mer required tens of minutes and dissociation could not be
induced by light. Therefore, dissociation was comparably slow
since it was based on the spontaneous hydrolysis of the ﬂavin-
FKF1 adduct that occurred within several hours [31].
While light-controlled molecular switches are currently the
method of choice to obtain external control of signaling pathways
due to their precise temporal and spatial control, the huge diversityof naturally occurring signaling molecules like growth factors [32],
guanine nucleotide binding switches [33] or the inversin switch in
theWnt signaling pathways [34] represents a large resource for the
construction of further molecular switches that are responsive to
internal or external stimuli.
2.3. Transcription control
The majority of the currently available inducible mammalian
gene expression systems is based on synthetic transcription factors
consisting of a eukaryotic transactivation or transsilencing domain
fused to a prokaryotic repressor protein that binds to its cognate
Fig. 2. Repression- and activation-based mammalian transcription control strategies. Both approaches rely on the small molecule-responsive interaction of a prokaryotic
repressor protein (R) with its cognate operator site (O). In the repression conﬁguration (upper panel), the repressor protein (optionally fused to a transsilencing domain (S))
binds to its operator and blocks transcription of the gene of interest (GOI). In the unbound state, the constitutive promoter (Pconst) is derepressed resulting in GOI
transcription. In the activation conﬁguration (lower panel), a synthetic transcription factor assembled of a transactivator domain (A) fused to the repressor protein binds to its
operator and activates a minimal promoter (Pmin). The release of the transcription factor from the operator results in deactivation of transcription. pA, poly(A) tail.
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moter and thereby either induces or represses gene expression
(Fig. 2 and Table 3). Since the afﬁnity of the chimeric transcription
factor to the operator sequence can be modulated by small
molecules, gene expression can be controlled in a reversible and
dose-dependent manner. While in previously developed systems
the regulating small molecules had to be taken up orally or admin-
istered by injection or inhalation [9], Gitzinger et al. engineered a
novel system for transdermal regulation of gene expression using
the apple metabolite phloretin which is commonly used as an anti-
oxidant in cosmetics [35]. In this system, the authors fused the
Pseudomonas putida transcriptional repressor TtgR to the Herpes
simplex VP16 transactivation domain and cloned the cognate oper-
ator sequence OTtgR 50 to a human cytomegalovirus-derived mini-
mal promoter PhCMVmin. With increasing phloretin concentrations,
the chimeric transcription factor TtgR-VP16 was dissociated from
its operator. This resulted in a dose-dependent deactivation of gene
expression by more than 99% compared to the fully activated state.
This engineered mammalian phloretin-adjustable control element
(PEACE) was tested in mice by subcutaneously implanting encap-
sulated Chinese hamster ovary (CHO) cells, which were stably
transfected for phloretin-induced expression of secreted alkaline
phosphatase (SEAP). By external application of skin lotion contain-
ing increasing amounts of phloretin, a decrease in the SEAP serum
level was observed [35]. In the future, this systemmight be a useful
tool for skin-related gene therapy approaches.
For the use of inducible mammalian gene expression systems in
prospective gene- and cell-based therapies, the selection of a trig-
ger molecule with optimal pharmacokinetic properties and mini-
mal side-effects is essential to obtain maximum speciﬁcity.
Therefore, Gitzinger et al. developed a novel transcription-control
device using the licensed food additive vanillic acid as trigger
[36]. Utilizing the transcriptional repressor VanR from Caulob-
acter crescentus that binds to its cognate operator VanO in the ab-
sence of vanillic acid, they constructed two gene expression
systems which either activate (VACON) or repress (VACOFF) gene
expression in the presence of vanillic acid. In the VACON system
the transcriptional silencer KRAB (Krueppel-associated box) was
fused C-terminally to VanR and an octameric VanO operator motif
was placed downstream of a constitutive human cytomegalovirus
immediate-early promoter (PhCMV). For the VACOFF system the
transactivation domain VP16 was fused to the C-terminus of VanR
and two VanO operator sequences were cloned upstream of aminimal version of the promoter PhCMV. Addition of vanillic acid
triggered the release of the chimeric transactivator (VanR-VP16)
or repressor (VanR-KRAB) from the corresponding promoter result-
ing in dose-dependent deactivation (65-fold, VACOFF) or dere-
pression (15-fold, VACON) of gene expression in Chinese
hamster ovary cells (CHO-K1). The functionality of the VACOFF sys-
tem was tested in vivo by intraperitoneally implanting microen-
capsulated CHO-K1 cells stably transfected with the VACOFF
system controlling SEAP expression into mice. It was shown that
administration of increasing vanillic acid amounts decreased SEAP
serum level in a dose-dependent manner similar to the in vitro
experiments. Since vanillic acid enabled robust, precise and tun-
able gene expression in mice and is a licensed food additive, it
could be used as a safe trigger molecule for diet-controlled trans-
gene expression in future gene- and cell-based therapies [36].
Recently, Ausländer et al. described a novel aptamer-based
approach to control transgene expression in mammalian cells
utilizing the well-characterized TET-OFF system (Fig. 3a) [37].
Aptamers are short nucleic acids that bind ligands such as small
molecules, proteins or other nucleic acids with high afﬁnity. Since
ligand-binding can induce a conformational change in the second-
ary structure, aptamers can be used for the construction of molec-
ular sensors. In the TET-OFF system, the transactivator domain
VP16 is fused to TetR forming the tetracycline-dependent transac-
tivator (tTA) which binds in the absence of tetracycline to its cog-
nate heptameric tetO operator sequence placed upstream of a
minimal promoter. To obtain tetracycline independent control
over this system, the theophylline aptamer was fused to a TetR
protein-inhibiting aptamer so that only in the presence of theoph-
ylline the functional structure of the TetR aptamer was restored.
Since the TetR aptamer was masking the tetO-binding helix-turn-
helix motif of TetR, addition of theophylline led to the dissociation
of tTA from its operator and subsequent inhibition of gene expres-
sion. Transfection of this system into human embryonic kidney
cells showed a dose-dependent deactivation (up to 5-fold) of gene
expression with increasing concentrations of theophylline [37]. In
the future, the usage of rationally designed aptamers to control
protein activity in response to a desired molecule could play an
important role in the ﬁeld of synthetic biology.
Since with small molecule-inducible gene expression systems it
is inherently difﬁcult to achieve localized or reversible gene
expression in a closed system, novel optogenetic tools were
developed to overcome these limitations. In 2009, Yazawa et al.
Table 3
Overview of switchable protein–DNA interactions used for the construction of synthetic regulatable promoters. Besides the design of the promoter and transcription factor, the
effect of the inducer molecule towards the transcription factor (TF) and transgene transcription (T) is shown (B, binding; D, dissociation; n.d., not determined) (A, activation; DA,
deactivation; DR, derepression). Based on the corresponding transcription factor, the synthetic promoters can be divided into transcriptional activator-responsive and repressor-
responsive promoters. Promoters that are sensitive towards multiple transcription factors are called hybrid promoters. HDAC4, human deacetylase 4 carboxy-terminal silencing
domain; KRAB, Krueppel-associated box protein-derived transcription silencer; p65, NFjB-derived transactivation domain; PCMV5, modiﬁed cytomegalovirus promoter; PhCMVmin,
minimal human cytomegalovirus promoter; PHPRT, hypoxanthine phosphoribosyltransferase promoter; Phsp70min, Drosophila-derived heat shock protein 70 minimal promoter;
PSV40, simian virus 40-derived promoter; VP16, Herpes simplex viral protein 16-derived transactivation domain.
System Promoter and operator Transcription factor (TF) Inducer molecule Response to inducer References
TF T
Transcriptional activator-responsive promoters
AIR PAIR (OalcA-PhCMVmin) AlcR Acetaldehyde n.d. A [76]
ART PART (OARG-PhCMVmin) ArgR-VP16 L-Arginine B A [77]
BIT PBIT3 (OBirA3-PhCMVmin) BIT (BirA-VP16) Biotin B A [78]
Cumate – activator PCR5 (OCuO6-PhCMVmin) cTA (CymR-VP16) Cumate D DA [79]
Cumate – reverse activator PCR5 (OCuO6-PhCMVmin) rcTA (rCymR-VP16) Cumate B A [79]
E-OFF PETR (OETR-PhCMVmin) ET (E-VP16) Erythromycin D DA [80]
NICE-OFF PNIC (ONIC-PhCMVmin) NT (HdnoR-VP16) 6-Hydroxy-nicotine D DA [81]
PEACE PTtgR1 (OTtgR-PhCMVmin) TtgA1 (TtgR-VP16) Phloretin D DA [35]
PIP-OFF PPIR (OPIR-Phsp70min) PIT (PIP-VP16) Pristinamycin I D DA [82]
QuoRex PSCA (OscbR-PhCMVmin)
PSPA (OpapRI-PhCMVmin)
SCA (ScbR-VP16) SCB1 D DA [83]
Redox PROP (OROP-PhCMVmin) REDOX (REX-VP16) NADH D DA [84]
TET-OFF PhCMV⁄-1 (OtetO7-PhCMVmin) tTA (TetR-VP16) Tetracycline D DA [85]
TET-ON PhCMV⁄-1 (OtetO7-PhCMVmin) rtTA (rTetR-VP16) Doxycycline B A [86]
TIGR PCTA (OrheO-PhCMVmin) CTA (RheA-VP16) Heat D DA [87]
TraR O7x(tra box)-PhCMVmin p65-TraR 3-Oxo-C8-HSL B A [88]
VAC-OFF P1VanO2 (OVanO2-PhCMVmin) VanA1 (VanR-VP16) Vanillic acid D DA [36]
Transcriptional repressor-responsive promoters
Cumate - repressor PCuO (PCMV5-OCuO) CymR Cumate D DR [79]
E-ON PETRON8 (PSV40-OETR8) E-KRAB Erythromycin D DR [80]
NICE-ON PNIC (PSV40-ONIC8) NS (HdnoR-KRAB) 6-Hydroxy-nicotine D DR [89]
PIP-ON PPIRON (PSV40-OPIR3) PIT3 (PIP-KRAB) Pristinamycin I D DR [82]
Q-ON PSCAON8 (PSV40-OscbR8) SCS (ScbR-KRAB) SCB1 D DR [90]
TET-ON, repressor-based OtetO-PHPRT tTS-H4 (TetR-HDAC4) Doxycycline D DR [91]
T-REX PTetO (PhCMV-OtetO2) TetR Tetracycline D DR [92]
UREX PUREX8 (PSV40-OhucO8) mUTS (KRAB-HucR) Uric acid D DR [54]
VAC-ON PVanON8 (PhCMV-OVanO8) VanA4 (VanR-KRAB) Vanillic acid D DR [36]
Hybrid promoters
QuoRex
PIP-ON
(NOT IF gate)
OscbR8-OPIR3-PhCMVmin SCA
PIT3
SCB1
Pristinamycin I
D
D
DA
DR
[93]
QuoRex
E-ON
(NOT IF gate)
OscbR-OETR8-PhCMVmin SCA
E-KRAB
SCB1
Erythromycin
D
D
DA
DR
(Kämpf submitted)
TET-OFF
E-ON
(NOT IF gate)
OtetO7-OETR8-PhCMVmin tTA
E-KRAB
Tetracycline
Erythromycin
D
D
DA
DR
[93]
TET-OFF
PIP-ON
E-ON
OtetO7-OPIR3-OETR8-PhCMVmin tTA
PIT3
E-KRAB
Tetracycline
Pristinamycin I
Erythromycin
D
D
D
DA
DR
DR
[93]
2088 M. Hörner, W. Weber / FEBS Letters 586 (2012) 2084–2096published the ﬁrst system to control transgene expression in mam-
malian cells using the blue light-dependent protein interaction
between FKF1 and GI [31]. In this system, the authors fused the
transactivation domain VP16 to FKF1 and generated a fusion pro-
tein of GI and the yeast DNA binding domain of Gal4 that bound
to its corresponding operator sequence OGal4 placed upstream of
a minimal promoter controlling luciferase expression. Illumination
with 450 nm light triggered recruitment of FKF1-VP16 to the
promoter and thereby induced luciferase expression ﬁvefold com-
pared to isogenic cells in the dark [31]. A similar light-induced
gene expression system was engineered by Kennedy et al. in yeast
utilizing the blue light-dependent interaction between Arabidopsis
thaliana cryptochrome 2 (CRY2) and CIB1 [38]. Upon illumination
with 461 or 488 nm light, the ﬂavin-binding protein CRY2 (amino
acids 1–498 or 1–612) interacted with a truncated version of CIB1
(CIBN, amino acids 1–170) in mammalian cells without the need of
an exogenous chromophore on a subsecond time scale and dissoci-
ated thereof in the dark within approximately 12 min. Kennedy
et al. also used this system to control DNA recombination in humanembryonic kidney cells (HEK-293T) by light-induced reconstitu-
tion of a split Cre recombinase [38]. For this purpose, they fused
CRY2 to the N-terminal part (amino acids 19–104) and CIBN to
the C-terminal part (amino acids 106–343) of Cre recombinase.
Using a reporter plasmid containing a transcriptional stop codon
ﬂanked by loxP sites upstream of a ﬂuorescent protein, they
showed 450 nm blue light-induced activation of split Cre recombi-
nase with a similar efﬁciency compared to chemical-induced
activation approaches [38].
2.4. Translation control
Translation can be controlled at the mRNA level by using stim-
ulus-responsive aptamers. Chen et al. developed an RNA-based
regulatory system to regulate translation of growth-stimulatory
cytokines in mammalian cells (Fig. 3b) [39]. In this system the
authors fused a theophylline- or tetracycline-binding aptamer to
a self-cleaving hammerhead ribozyme and cloned it into the 30
untranslated region (UTR) of a cytokine-coding target transgene.
Fig. 3. Aptamer-based gene expression regulation strategies. (a) Aptamer-based approach to regulate transcription of a target gene of interest (GOI). The system was based on
the TET-OFF system in which a synthetic transcription factor consisting of the transactivator domain VP16 (A) fused to the tetracycline repressor TetR binds in the absence of
tetracycline to its cognate heptameric tetO operator site placed upstream of a minimal promoter (PhCMVmin) thus inducing transcription. To achieve tetracycline-independent
transcription control, a theophylline-binding aptamer was fused via a transmitter sequence to a TetR-inhibiting aptamer. In the absence of theophylline, the TetR aptamer
was non-functional while binding of theophylline induced a conformational change that restored the TetR aptamer structure. Therefore, the TetR aptamer bound to TetR and
masked its tetO-binding helix-turn-helix motif resulting in dissociation of TetR-VP16 from the operator site and deactivation of transcription. (b) RNA-based regulatory
device for translation control of growth-stimulatory cytokines in mammalian cells. A self-cleaving hammerhead ribozyme was fused via a transmitter sequence to a drug-
binding aptamer and cloned in the 30 untranslated region of an interleukin-2 (IL-2) coding transgene. In the absence of the aptamer-binding drug, the ribozymewas active and
underwent self-cleavage. Therefore, the poly(A) tail (pA) was separated from the open reading frame resulting in rapid degradation of the mRNA. However, binding of the
drug to the aptamer induced a conformational change that switched the ribozyme inactive. Therefore, the integrity of the transcript was preserved permitting effective
translation.
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went self-cleavage and thereby removed the poly(A) tail from the
open reading frame resulting in rapid degradation of the target
transcript and subsequently decreased cytokine expression. How-
ever, binding of the drug to the aptamer induced a conformational
change that inactivated the ribozyme and thereby preserved theintegrity of the transcript allowing effective cytokine production.
This synthetic RNA-based regulatory device was used to control
primary human T-cell proliferation in vitro and to modulate
the growth rate of transgenic T-cells, which were encased in a
hydrogel matrix and implanted into mice, by external drug
application [39].
2090 M. Hörner, W. Weber / FEBS Letters 586 (2012) 2084–2096Synthetic RNA devices can also be used to make cellular behav-
ior responsive to endogenous protein levels. In 2010, Culler et al.
engineered a novel RNA based sensor-actuator device that coupled
intracellular protein concentrations to targeted gene expression
events [40]. This device consisted of a three-exon, two-intron
mini-gene that was placed upstream of the transgene. Alternative
splicing of the mini-gene was controlled by speciﬁc protein bind-
ing aptamers located in the intron sequences. At high nuclear con-
centration of the sensed protein the middle exon which contained
a stop codon was spliced out probably due to steric hindrance or
recruitment of spliceosome site recognition factors. Exclusion of
the stop codon led to high transgene expression (two- to four-fold
induction) while at low protein concentrations the central exon
remained unspliced resulting in a low expression level of the trans-
gene. The device was designed to sense subunits of the transcrip-
tion factor NF-jB or the signaling protein b-catenin in order to
express the Herpes simplex thymidine kinase at high nuclear
protein concentrations of these cancer markers. In the presence
of the prodrug ganciclovir, expression of the thymidine kinase
induced a cytotoxic effect [40].Fig. 4. Different strategies to regulate targeted protein degradation in mammalian ce
rapamycin-binding protein FKBP12 was fused to the protein of interest (POI). Since the DD
However, binding of the small molecule Shield-1 to the DD prevented from degradation
LID domain comprising a mutated FKBP12 protein and a carboxy-terminal cryptic degrad
was bound to the active site of FKBP12 thus preventing degradation, while binding of
domain and the fused POI. Since the DD and LID system are utilizing the same inducer m
target proteins in the same cell. (b) The auxin-based protein degradation system from pla
and a fusion protein of Arabidopsis thaliana IAA transcription repressor 17 (Aid) and POI.
comprising the auxin receptor TIR1 and the endogenous mammalian SCF complex. Si
ubiquitinated (U) leading to rapid degradation by the proteasome.2.5. Regulation of protein degradation
Besides controlling cellular protein concentration at the tran-
scriptional or translational level, protein abundance can be regu-
lated by targeted protein depletion. By fusing a destabilizing
domain (DD) to the desired protein, Banaszynski et al. developed
a general method to control the stability of speciﬁc proteins with
small synthetic, cell-permeable molecules in mammalian cells
(Fig. 4a) [41]. For this purpose they screened for mutants of the
FK506- and rapamycin-binding protein FKBP12 (107 amino acids)
that are rapidly and constitutively degraded but stabilized in the
presence of an FKBP12-binding ligand like Shield-1. Since the
FKBP12-derived protein instability is conferred to a fused protein,
the fusion protein is constitutively degraded in the absence of
Shield-1 while binding of this small molecule to the destabilizing
domain protects from degradation permitting the fused protein
to execute its cellular function. By fusing the most destabilizing
FKBP12 mutant (F36V and L106P) to YFP and stably expressing
the obtained fusion protein in NIH/3T3 mouse ﬁbroblasts, the ﬂuo-
rescence intensity was reduced by 98–99% compared to its max-
imum level which was restored by addition of 1 lM Shield-1. Thells. (a) In the destabilizing domain (DD) system, a DD based on the FK506- and
instability was conferred to the fused protein, the POI was constitutively degraded.
and stabilized the fusion protein. In the ligand-induced degradation (LID) system, a
ation sequence (degron, D) was fused to POI. In the absence of Shield-1, the degron
Shield-1 to the active site displaced the degron resulting in degradation of the LID
olecule, Shield-1 could be used to simultaneously stabilize and destabilize speciﬁc
nts was transferred to mammalian cells by transgenic expression of Oryza sativa TIR1
Addition of auxin induced the interaction between Aid and a multi-protein complex
nce the SCF complex contains a ubiquitylation system, the POI was subsequently
M. Hörner, W. Weber / FEBS Letters 586 (2012) 2084–2096 2091DD system had the drawback that it required constant application
of Shield-1 to cells in order to preserve protein function [41].
Therefore, the same research group recently developed an
FKBP-based ligand-induced degradation (LID) system (Fig. 4a)
[42]. Similar to the destabilizing domain approach, the LID domain
consisting of a mutated FKBP12 protein with a carboxy-terminal
19-amino-acid cryptic degradation sequence (degron) was fused
to a protein of interest. In the absence of an FKBP12-binding ligand
the degron bound to the active site of FKBP12 preventing degrada-
tion. However, binding of Shield-1 to FKBP12 displaced the degron
and thereby induced degradation of LID and the fused protein by
80–90% compared to the absence of Shield-1. With this LID system,
Shield-1-induced degradation was shown in mammalian cells for
various proteins including transcription factors and actin [42]. By
combining the LID system with the DD approach in the same cell,
Shield-1 could be used to simultaneously stabilize and destabilize
speciﬁc target proteins.
An alternative inducible and reversible protein degradation
system based on the auxin-based degron system from plants was
described by Nishimura et al. (Fig. 4b) [43]. In plants, the phytohor-
mone auxin triggers the interaction between the auxin or indole-3-
acetic acid (IAA) transcription repressor and the multi-protein
complex SCF-TIR1 containing, among others, an E3 ubiquitin ligase
and the auxin receptor TIR1. Upon auxin-induced heterodimeriza-
tion, the auxin/IAA transcription repressor is polyubiquitinated
resulting in rapid degradation by the proteasome. Since the SCF
complex is conserved throughout eukaryotes, the auxin-inducible
degron system could be transferred to non-plant cells by trans-
genic expression of TIR1 and the auxin/IAA transcription repressor.
By stably expressing Oryza sativa TIR1 and a fusion protein of
Arabidopsis thaliana IAA transcription repressor 17 (Aid) and GFP
in HEK-293 cells, rapid (10 min half-life) and efﬁcient (97%)
degradation of GFP was induced by the addition of the auxin hor-
mone IAA. The functionality of the system was shown in further
mammalian as well as in yeast and avian cells [43].3. Syntheticsignaling networks – open- and closed-loop control
systems
In the ﬁrst part of this review, various molecular switches for
the control of cellular processes were discussed. In the second part
we describe, how these building blocks can be combined in a
rational and systematic manner to complex engineered synthetic
biological products like synthetic signaling networks. While the
ﬁrst synthetic networks such as the toggle switch [44] or the ﬁrst
synthetic mammalian oscillators [45,46] were ground-breaking
proof of principle studies, the development is currently moving
towards therapeutic applications. Since many diseases are caused
or characterized by deviations of speciﬁc molecules from their
physiological level, it is expected that next-generation therapeutic
signaling networks are connected to host physiology by sensing
and responding to endogenous molecules. These networks can be
divided into open- and closed-loop control systems. In open-loop
systems the output has no effect on its regulating input while in
closed-loop systems the output of the system affects its input via
a feedback loop. In the following, an open-loop artiﬁcial insemina-
tion and a synthetic optogenetic transcription device as well as
three closed-loop ‘‘molecular prostheses’’ that autonomously de-
tect and cure a disease state are described.
3.1. Artiﬁcial insemination device for cattle reproduction
The reproduction of cattle is routinely performed by artiﬁcial
insemination but the synchronization between sperm administra-
tion and cow estrus remains still the major challenge in increasingthe fertilization efﬁciency [47]. To address this problem, Kemmer
et al. engineered a synthetic genetic switch with an open-loop con-
trol strategy that triggers the release of bull sperms out of an in
utero implanted polymer capsule upon detection of ovulation, as
characterized by a transient peak in luteinizing hormone (LH)
(Fig. 5a) [48]. For this purpose, the rat luteinizing hormone recep-
tor (rLHR) was expressed in HEK-293 cells, the stimulation of
which with LH led to an increase of the intracellular cAMP concen-
tration. The elevated cAMP level was linked via the endogenous
cAMP-responsive element binding protein 1 (CREB1) to the induc-
ible expression of Bacillus subtilis-derived secretion-engineered
cellulase (endo-1,4-beta-glucanase). After encapsulation of the
genetically engineered cells together with bull sperms into cellu-
lose-sulfate/pDADMAC (poly-diallyldimethyl ammonium chloride)
microcapsules, LH treatment triggered sperm release by inducing
cellulase secretion and subsequent capsule degradation [48,49].
Implantation of these microcapsules into the uterus of dairy cows
successfully showed capsule degradation, sperm release, oocyte
fertilization and initial embryo development after hormonal estrus
induction [48].
3.2. Synthetic optogenetic transcription device for the treatment of
diabetes
Diabetes is a common metabolic disease which is characterized
by a chronic elevation of serum glucose levels [50]. In order to eval-
uate a novel treatment strategy, Ye et al. recently constructed a
synthetic optogenetic transcription device for the light-controlled
enhancement of blood glucose homeostasis (Fig. 5b) [51]. As light
sensor, they applied melanopsin, a GPCR derived from intrinsically
photosensitive retinal ganglion cells (ipRGCs). Transfection of HEK-
293 cells with both a melanopsin and a PNFAT-driven SEAP reporter
construct was sufﬁcient to obtain 470 nm blue light-triggered SEAP
expression. Brieﬂy, blue light-induced photo-isomerization of the
melanopsin-bound chromophore 11-cis-retinal resulted in a con-
formational change in melanopsin and following sequential activa-
tion of the Gaq-type G-protein, phospholipase C (PLC), and
phosphokinase C (PKC). This induced the inﬂux of Ca2+ into the
cytosol by activation of transient receptor potential channels
(TRPCs) and potentially by release of Ca2+ from intracellular stor-
age organelles like the endoplasmic reticulum. The blue light-trig-
gered calcium inﬂux was linked to NFAT signaling by the calcium
sensor calmodulin (CaM) which activated the serine/threonine
phosphatase calcineurin (CaN). Thus, the serine-rich region and
serine-proline repeats in the N-terminus of the transcription factor
NFAT were dephosphorylated leading to the exposure of a nuclear
import signal and translocation of NFAT into the nucleus where it
bound to its cognate promoter (PNFAT) and induced transgene
expression. The transgenic blue light-triggered SEAP producing
HEK-293 cells were implanted either intraperitoneally in hollow ﬁ-
ber containers or subcutaneously microencapsulated into mice.
Using optical ﬁbers or direct transdermal blue light illumination,
expression of SEAP and thus its serum level were externally con-
trolled. Moreover, after implanting cells engineered for the mela-
nopsin-triggered expression of the glucagon-like peptide 1
(GLP1) into a human type II diabetic mouse model, blue light
was used to attenuate glycemic excursions and to enhance
blood-glucose homeostasis [51].
3.3. Synthetic urate homeostasis network for the treatment of gouty
arthritis
More than 1% of humans in industrialized countries are affected
by gouty arthritis. This disease is characterized by a serum uric
acid level above the solubility limit leading to the formation of uric
acid crystals in joints, kidney and subcutaneous tissues causing
Fig. 5. Synthetic signaling networks. (a) Artiﬁcial insemination device for cattle reproduction. Bull sperms and genetically engineered HEK-293 sensor-actuator cells were
encapsulated and implanted into the uterus of dairy cows. Upon ovulation, which is characterized by a transient peak in luteinizing hormone (LH), LH bound to the rat
luteinizing hormone receptor (rLHR) on the cell surface and thereby induced an increase in intracellular cAMP. Utilizing the endogenous cAMP-responsive element binding
protein 1 (CREB1), the elevated cAMP level was linked to the inducible expression of a secretion-engineered cellulase. Subsequently, the cellulose-sulfate capsule was
degraded and the sperms were released. (b) Synthetic optogenetic transcription device for enhanced blood-glucose homeostasis. The light-induced melanopsin signaling
pathway was rewired with the nuclear factor of activated T cells (NFAT) control circuit. Upon blue light-induced photo-isomerization of the melanopsin-bound chromophore
11-cis-retinal (R), the Gaq-type G-protein, phospholipase C (PLC), and phosphokinase C (PKC) were sequentially activated. This cascade resulted in the inﬂux of Ca2+ into the
cytosol by activation of transient receptor potential channels (TRPCs) and potentially by release of Ca2+ from the endoplasmic reticulum (ER). The elevated Ca2+ level was
sensed by the calcium sensor protein calmodulin (CaM) which activated the phosphatase calcineurin (CaN) resulting in dephosphorylation of the transcription factor NFAT.
Thus, NFAT translocated into the nucleus where it bound to its cognate promoter (PNFAT) and induced expression of glucagon-like peptide 1 (GLP1). This system was used to
enhance blood-glucose homeostasis in a human type II diabetic mouse model by illumination with blue light. (c) Synthetic urate homeostasis network for the treatment of
gouty arthritis. Microencapsulated genetically engineered sensor-actuator cells were implanted into mice. Extracellular urate from the blood vessels was imported into these
cells via the transgenic human urate anion transporter URAT1. At physiological urate levels, the constitutively expressed transsilencer KRAB-HucR bound to its cognate
operator hucO8 and repressed expression of a secretion-engineered urate oxidase (smUOX). However, elevated pathological urate levels dose-dependently decreased the
binding of KRAB-HucR to its operator resulting in derepression of smUOX expression. Therefore, the urate oxidase was secreted out of the cell where it mediated the
conversion of urate into the more soluble and renally secretable allantoin. pA, poly(A) tail.
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a free radical scavenger, moderate urate levels are beneﬁcial and
must be sustained [53]. With the aim of developing a novel thera-
peutic approach, Kemmer et al. engineered a prosthetic network
that constantly monitors and, if necessary, reduces serum uric acid
concentration to the physiological level by on-demand expression
of a urate oxidase (Fig. 5c) [54].In this prosthetic network, the uric
acid sensor HucR from Deinococcus radiodurans, which binds to its
operator sequence hucO in the absence of uric acid, was used. The
engineered closed-loop genetic circuit consisted of a constitutively
expressed fusion protein of HucR linked carboxy-terminally to the
transcriptional silencer KRAB and a secretion-engineeredAspergillus ﬂavus urate oxidase (smUox) under the control of a sim-
ian virus 40-derived promoter fused in 50 to an octameric hucO
motif. At low uric acids level, KRAB-HucR bound to hucO and re-
pressed smUox transcription while high uric acids concentrations
induced dissociation of the repressor and subsequent derepression
of urate oxidase expression. To distinguish between pathological
and physiological uric acid concentrations, the sensitivity of the
prosthetic network was increased by coexpression of the human
urate anion transporter URAT1 in order to obtain an enhanced
cellular urate level. To test the functionality of this uric acid-
responsive expression network (UREX), microencapsulated UREX-
transgenic HeLa cervix carcinoma cells were intraperitoneally
Fig. 6. Synthetic signaling networks for the identiﬁcation of cancer cells. (a) Dual-promoter expression integrator. This AND-type Boolean gate was based on the expression of
the fusion proteins DocS-VP16 and Gal4BD-Coh2 by two independent native cancer-sensing promoters (P1 and P2). Only the expression of both fusion proteins resulted in the
reconstitution of a chimeric transcription factor via the heterodimer-forming proteins DocS and Coh2. This factor bound its cognate Gal4 operator placed in 50 of a minimal
promoter and induced expression of Herpes simplex virus type 1 thymidine kinase (TK1) via its VP16 transcription activation domain. In the presence of the nucleotide
analogue ganciclovir, expression of TK1 induced cell death. Adapted from [1]. (b) RNAi-based cell-type classiﬁer. The gene of interest (GOI, e.g. hBax) was expressed only
when the preset expression level of the endogenous microRNAs (miRNA 1–2 high, miRNA 3–5 low) was matched. The cell-type classiﬁer was assembled out of high and low
miRNA sensors. One high miRNA sensor consisted of a constitutively transcribed reverse tetracycline controlled transactivator (rtTA) which triggered expression of the
transcriptional Lac repressor LacI. Binding of LacI to its cognate operator site placed downstream of a constitutive CAG promoter (CAGop) repressed GOI transcription. Since
both the rtTA and lacI gene contained target sites (TS) for the sensed miRNA in their 30 untranslated region (UTR), a high expression level of the corresponding miRNA
repressed translation of rtTA and LacI and thus derepressed expression of the GOI. Two high miRNA sensors were integrated on the level of rtTA and LacI in order to control
the same CAGop output promoter in parallel. As low miRNA sensors, target sites for the sensed miRNAs were placed in the 30 UTR of the GOI. Therefore, only at low miRNA
levels the GOI could be translated since high expression levels of the corresponding miRNAs induced degradation of the mRNA.pA, poly(A) tail.
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hyperuricemia. It was shown, that the prosthetic network stably
decreased serum uric acid concentration to a sub-pathological le-
vel resulting in dissociation of uric acid crystals in the kidney while
maintaining a physiological radical-scavenging concentration [54].
3.4. Dual-promoter expression integrator for cancer treatment
Gene therapeutic approaches for cancer therapy include genetic
circuits that trigger expression of toxic gene products in malignant
cells while leaving healthy tissues unaffected. In the past, several
approaches were described where this discrimination was
achieved using a highly active context-speciﬁc promoter [55,56].
Since a single-promoter approach only allows linear responses
and inherently suffers from noise, false-positive identiﬁcation
and lack of speciﬁcity, Nissim and Bar-Ziv engineered a dual-pro-
moter expression integrator (DPI) for improved identiﬁcation of
cancer cells (Fig. 6a) [57]. This AND-type Boolean gate was basedon the formation of a chimeric transcription factor consisting of
the yeast Gal4 DNA-binding domain and the VP16 transcription
activation domain which interacted via the heterodimer-forming
bacterial proteins DocS and Coh2. Only the expression of both fu-
sion proteins DocS-VP16 and Gal4BD-Coh2 by two independent na-
tive cancer-sensing promoters resulted in the reconstitution of a
chimeric transcription factor. This factor activated a synthetic
promoter containing ﬁve Gal4 operator sites driving luciferase or
Herpes simplex virus type 1 thymidine kinase (TK1) expression
which is cytotoxic in the presence of nucleotide analogues such
as ganciclovir. To discriminate tumor cells from premalignant ones,
promoters controlling transcription of cancer-speciﬁc genes like
H2A1 (chromatin structural protein histone-H2A1), SSX1 (synovial
sarcoma X-breakpoint protein-1) or CXCL1 (inﬂammatory chemo-
kine) were chosen for the expression control of the split transcrip-
tion factors. The functionality of the system was tested by
transfecting the DPI into premalignant lung ﬁbroblasts and differ-
ent malignant cancer cell lines. While in the premalignant cells
2094 M. Hörner, W. Weber / FEBS Letters 586 (2012) 2084–2096only background activity of the synthetic output promoter was ob-
served, the output signal showed a digital-like increase in malig-
nant cells with an overall intensity much higher than the same
luciferase reporter under the direct control of the individual can-
cer-speciﬁc promoters. Since the afﬁnity between the heterodi-
mer-forming proteins was able to be modulated, the system
could easily be adapted to the strength of the input promoters or
the desired target gene expression level [57].
3.5. RNAi-based cell-type classiﬁer for cancer therapy
Xie et al. engineered a cell-type classiﬁer which triggers expres-
sion of a target gene in response to a predeﬁned intracellular state
similar to the dual-promoter expression integrator (Fig. 6b) [58].
Their RNAi-based logic circuit sensed the expression level of up
to six endogenous microRNAs (miRNAs) and triggered expression
of an output gene only if the miRNA expression pattern matched
a preset proﬁle. The device was assembled out of high and low
miRNA sensors which drove expression of the output gene only
when the corresponding miRNAs were present at high or low lev-
els, respectively. The high miRNA sensor consisted of a constitu-
tively transcribed reverse tetracycline controlled transactivator
(rtTA) which induced expression of the transcriptional Lac repres-
sor (LacI). Since the 30 UTR of both genes was engineered to com-
prise target sites for the sensed miRNA, translation of rtTA and
LacI was repressed at a high miRNA level. This resulted in expres-
sion of the output gene which was under regulation of the LacI-
controlled promoter CAGop (two LacO sites downstream of a con-
stitutive CAG promoter). In the low miRNA sensor, four repeats of
fully complementary miRNA target sites were placed into the 30
UTR of the output gene, inhibiting mRNA translation at a high
expression level of the corresponding miRNA. Multiple low miRNA
sensors were integrated by including the different miRNA target
sequences into the 30 UTR of the same output gene while multiple
high miRNA sensors were combined by regulating the same CAGop
output promoter in parallel. Using this cell-type classiﬁer, HeLa
cells could selectively be identiﬁed based on two up- and three
down-regulated miRNAs and afterwards killed by the expression
of the apoptosis-inducing human Bcl-2-associated X protein hBax
[58].
4. Outlook
During the past years a huge diversity of molecular switches
have been engineered and characterized. Especially, the emerging
ﬁeld of optogenetics is opening a new era in biomedical research
since light-dependent molecular switches allow fast and reversible
control with a unique spatial resolution compared to classical
chemical-based approaches [12,59]. Due to their modularity, com-
patible molecular switches can be reassembled in a rational and
predictive manner to complex synthetic signaling networks. Since
the construction of signaling networks is limited by the availability
of the underlying molecular switches, further research on the
development of molecular switches is essential. The recent devel-
opment of complex synthetic signaling networks impressively
shows that the ﬁeld of synthetic biology is currently moving from
the initial proof-of-concept studies towards useful therapeutic
applications. However, the key challenge in the medical
application of synthetic therapeutic signaling networks remains
in the transfer into the human body. While prosthetic networks
like the synthetic urate homeostasis network [54] could be
transferred to humans by implantation of externally transfected
microencapsulated cells or an ex vivo cell therapy, systems like
the dual-promoter expression integrator [57] or the RNAi-based
cell-type classiﬁer [58] for cancer therapy must be integrated intothe target cells by an in vivo gene therapeutic approach. Given the
tremendous progress in gene therapy with regard to the develop-
ment of safe vectors and targeted transgene integration strategies
into safe genomic harbors [60], the treatment of patients with syn-
thetic signaling networks is in reach for therapeutic reality.
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